{"entity":{"id":"af-hpa","kind":"term","name":"AF-HPA and auristatin F","aka":["AF-HPA","auristatin F-hydroxypropylamide","Auristatin F-hydroxypropylamide"],"tldr":"AF-HPA is an auristatin cargo used in the Dolaflexin platform. It can convert to active auristatin F, which has less access across membranes.","summary":"The Dolaflexin preclinical studies distinguish membrane-accessible auristatin F-hydroxypropylamide, or AF-HPA, from its less membrane-accessible but still active auristatin F metabolite. Auristatin F is not the same chemical as monomethyl auristatin F.\n\nThe XMT-1536 preclinical report describes roughly 10 to 15 AF-HPA molecules per antibody. This is a preparation-specific report, rather than a fixed mean or a common loading of eight. The earlier polyacetal Fleximer study used a vinca derivative; its platform name must not be treated as evidence for Dolaflexin composition. Cell and animal activity does not establish patient benefit or complete payload confinement.","asOf":"2026-11-09","links":[{"label":"Dolaflexin: AF-HPA and auristatin F in preclinical models (2021)","url":"https://pubmed.ncbi.nlm.nih.gov/33722857/"},{"label":"XMT-1536 preclinical composition and NaPi2b-directed models (2021)","url":"https://pubmed.ncbi.nlm.nih.gov/33722858/"},{"label":"Polyacetal Fleximer with a vinca derivative, a distinct platform (2015)","url":"https://pubmed.ncbi.nlm.nih.gov/26113086/"}],"tags":[],"related":["bystander-effect","efflux-pump"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":["upifitamab-rilsodotin"],"companies":[],"institutions":[],"pathways":[],"terms":["payload","tubulin-inhibitor-payloads"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry","chemicalObservations":[{"sources":[{"label":"Dolaflexin: AF-HPA and auristatin F in preclinical models (2021)","url":"https://pubmed.ncbi.nlm.nih.gov/33722857/"}],"checkedOn":"2026-11-09","species":{"name":"AF-HPA"},"context":"Dolaflexin preclinical conjugate and metabolite studies.","method":"Cell and animal characterisation.","statement":"Membrane-accessible AF-HPA can convert to the less membrane-accessible but active auristatin F species.","evidenceType":"experimental","limitation":"Auristatin F is distinct from MMAF; the conversion does not establish complete confinement or human safety.","property":"release"},{"sources":[{"label":"XMT-1536 preclinical composition and NaPi2b-directed models (2021)","url":"https://pubmed.ncbi.nlm.nih.gov/33722858/"}],"checkedOn":"2026-11-09","species":{"name":"AF-HPA"},"conjugate":{"name":"XMT-1536"},"context":"The named XMT-1536 product or preparation described by the source.","method":"Composition reported for the preclinical conjugate preparation.","statement":"The preclinical report describes approximately 10 to 15 AF-HPA molecules per antibody; no fixed mean is inferred from that range.","evidenceType":"experimental","limitation":"This report does not assign a loading constant to every construct carrying this cargo or infer a patient dose.","property":"conjugate-loading"}]},"route":"/terms/af-hpa/","neighbours":{"term":[{"id":"bystander-effect","kind":"term","name":"Bystander effect (ADC)","route":"/terms/bystander-effect/"},{"id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/"},{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"upifitamab-rilsodotin","kind":"drug","name":"Upifitamab rilsodotin","route":"/drugs/upifitamab-rilsodotin/"}]}}